Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00382018 · ClinicalTrials.gov registry record · Phase 3

S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo

A Phase 3 study, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 3
Development phase
624
Enrollment target

NCT00382018 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 624 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00382018, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 3
Development phase
624 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Measuring blood levels of tumor cells may help in learning how well chemotherapy works to kill metastatic breast cancer cells and allow doctors to plan better treatment. When blood levels of tumor cells are high while receiving chemotherapy, it is not yet known whether it is more effective to change chemotherapy regimens at that time or wait until disease progression. PURPOSE: This randomized phase III trial is studying treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy.

Interventions

  • DRUG chemotherapy

Trial Details

FieldValue
Enrollment Target 624 participants
Start Date 2006-10
Est. Completion 2017-07-11
Phase Phase 3

Sponsor

SWOG Cancer Research Network

270 total trials

What the Registry Record Tells You About NCT00382018

The ClinicalTrials.gov registry entry for NCT00382018 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 624 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which chemotherapy is the first listed.

NCT00382018 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00382018 about?

NCT00382018 is a clinical study titled "S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo". RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Measuring blood levels of tumor cells may help in learning how well chemotherapy works to kill metastatic breast cancer cells and allow docto...

What is the current status of trial NCT00382018?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 624 participants. The study started on 2006-10. Estimated completion is 2017-07-11.

What interventions are being tested in trial NCT00382018?

The interventions under investigation include: chemotherapy (DRUG).

Who is sponsoring clinical trial NCT00382018?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.